Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Abstract Text:

W P Dillon,H Rowley,

Visual disturbance, hypertension, convulsions, and unconsciousness developed in a 70-year-old man after cisplatin chemotherapy and upper-limb amputation for osteosarcoma. MR imaging revealed bilateral reversible abnormalities in the occipital, parietal, and frontal white matter. Clinical and neuroradiologic features corresponded to reversible posterior leukoencephalopathy syndrome (RPLS), which some immunosuppressive and chemotherapeutic drugs have been reported to trigger. Cisplatin may be among these drugs. Our patient also had hypomagnesemia, which may have figured in the pathophysiology.

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Publishing Authors By Initials

WP Dillon,H Rowley,

For similar male research abstracts see: male research

PUBMED ID PMID:

MEDLINE DATE:

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: AJNR. American journal of neuroradiology

VOLUME: 19

Page Numbers: 415-7

Journal Abbreviation:

ISSN: 0195-6108

DAY: 14

MONTH: Mar

YEAR: 1998

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8003708

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Keywords Mesh Terms:

KEYWORDS: Male

MESH TERMS: diagnosis

Chemical & Substance for Abstract: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. Information

Substance Name: Cisplatin

Registry Number: 15663-27-1

Grant and Affiliation Information for Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.

AFFILIATION: Department of Neurology, Nagoya University School of Medicine, Japan.

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: AJNR Am J Neuroradiol

REFSOURCE: AJNR Am J Neuroradiol. 1998 Mar;19(3):59

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome Related Publications

• A message from the New Editor-in-Chief.
• A novel centrosomal ring-finger protein, dorfin, mediates ubiquitin ligase activity.
• CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA.
• Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries.
• Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome.
• Clinicopathologic characteristics of five autopsied cases of dura mater-associated Creutzfeldt-Jakob disease.
• Contrast-enhanced 2D cine phase MR angiography for measurement of basilar artery blood flow in posterior circulation ischemia.
• Correlation between multiple phosphorylation of gizzard myosin light chains and actin-activated myosin ATPase activity.
• Cyclosporin A inhibits late steps of T lymphocyte activation after transmembrane signaling.
• Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease.
• Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1.
• Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.
• Dorfin prevents cell death by reducing mitochondrial localizing mutant superoxide dismutase 1 in a neuronal cell model of familial amyotrophic lateral sclerosis.
• Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity.
• Dual roles of myocardin-related transcription factors in epithelial mesenchymal transition via slug induction and actin remodeling.
• Isolation and characterization of a calmodulin binding fragment of chicken gizzard caldesmon.
• Multiple cerebellar infarcts: clinical and pathophysiologic features.
• Nonmyelinating Schwann cell involvement with well-preserved unmyelinated axons in Charcot-Marie-Tooth disease type 1A.
• Physical and functional interaction between Dorfin and Valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders.
• Pupillary supersensitivity and visual disturbance in Parkinson's disease.
• Pyramidal tract degeneration in sporadic Creutzfeldt-Jakob disease.
• Quantitative determinations of calmodulin in the supernatant and particulate fractions of mammalian tissues.
• Small neurons may be preferentially affected in ganglionopathy.
• The Japan cancer surveillance report: incidence of childhood, bone, penis and testis cancers.
• The video images of sleep attacks in Parkinson's disease.
• Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy.
• [Animal models of neurodegenerative diseases on the road to disease-modifying therapy: spinal and bulbar muscular atrophy]
• [Envisioning quality measurement systems of cancer care]
• [Gene expression profile of spinal ventral horn in ALS]
• [Neurodegenerative diseases and Dorfin]